Press releases | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

24 May 2022

Transparency notification FMR LLC

Read More
23 May 2022

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

Read More
23 May 2022

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

Read More
20 May 2022

Disposal of own shares

Read More
18 May 2022

Transparency notification Wellington

Read More
13 May 2022

Disposal of own shares

Read More

Stay up-to-date on the latest news and information from UCB